Latest Insider Transactions at Avantor, Inc. (AVTR)
This section provides a real-time view of insider transactions for Avantor, Inc. (AVTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Avantor, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Avantor, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2023
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
106,200
-8.3%
|
$2,124,000
$20.28 P/Share
|
|
May 17
2023
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
12,449
-11.77%
|
$248,980
$20.28 P/Share
|
|
May 17
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
15,706
-15.92%
|
$314,120
$20.28 P/Share
|
|
May 17
2023
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
18,917
-18.14%
|
$378,340
$20.28 P/Share
|
|
May 17
2023
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,261
-23.09%
|
$465,220
$20.28 P/Share
|
|
May 17
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
2,210
-1.18%
|
$44,200
$20.28 P/Share
|
|
May 17
2023
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
553
-2.54%
|
$11,060
$20.28 P/Share
|
|
May 17
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
19,683
-18.11%
|
$393,660
$20.28 P/Share
|
|
May 11
2023
|
Juan Andres Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+19.73%
|
-
|
|
May 11
2023
|
Joseph R Massaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+34.7%
|
-
|
|
May 11
2023
|
Lan Kang Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+31.09%
|
-
|
|
May 11
2023
|
Jonathan M Peacock Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+5.01%
|
-
|
|
May 11
2023
|
John Carethers Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+32.6%
|
-
|
|
May 11
2023
|
Mala Murthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+34.49%
|
-
|
|
May 11
2023
|
Gregory L Summe Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+23.16%
|
-
|
|
May 11
2023
|
Michael Severino Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+21.9%
|
-
|
|
May 11
2023
|
Christi Shaw Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,808
+21.29%
|
-
|
|
Apr 16
2023
|
Randy Lee Stone EVP, Laboratory Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
48,332
+50.0%
|
-
|
|
Apr 11
2023
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
1,498
-1.5%
|
$31,458
$21.18 P/Share
|
|
Apr 05
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
569
-0.56%
|
$11,380
$20.82 P/Share
|
|
Mar 03
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,914
-3.48%
|
$97,850
$25.0 P/Share
|
|
Feb 28
2023
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
2,324
-2.26%
|
$55,776
$24.32 P/Share
|
|
Feb 27
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,059
-2.64%
|
$76,475
$25.0 P/Share
|
|
Feb 25
2023
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
505
-2.27%
|
$12,120
$24.62 P/Share
|
|
Feb 25
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
2,040
-1.73%
|
$48,960
$24.62 P/Share
|
|
Feb 25
2023
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,685
-0.6%
|
$184,440
$24.62 P/Share
|
|
Feb 25
2023
|
Sheri Lewis EVP, Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
1,340
-1.75%
|
$32,160
$24.62 P/Share
|
|
Feb 25
2023
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
560
-0.53%
|
$13,440
$24.62 P/Share
|
|
Feb 25
2023
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
511
-0.49%
|
$12,264
$24.62 P/Share
|
|
Feb 25
2023
|
Meghan Henson EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
800
-1.95%
|
$19,200
$24.62 P/Share
|
|
Feb 25
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-0.45%
|
$11,208
$24.62 P/Share
|
|
Feb 25
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
299
-0.16%
|
$7,176
$24.62 P/Share
|
|
Feb 25
2023
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,040
-1.91%
|
$48,960
$24.62 P/Share
|
|
Feb 24
2023
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,347
+19.38%
|
-
|
|
Feb 24
2023
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
20,308
+14.71%
|
-
|
|
Feb 24
2023
|
Kitty Sahin EVP, Strategy&Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+23.86%
|
-
|
|
Feb 24
2023
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
99,004
+7.14%
|
-
|
|
Feb 24
2023
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+13.73%
|
-
|
|
Feb 24
2023
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,138
+7.91%
|
-
|
|
Feb 24
2023
|
James Bramwell EVP Sales, Customer Excellence |
BUY
Grant, award, or other acquisition
|
Direct |
20,308
+16.23%
|
-
|
|
Feb 24
2023
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+22.92%
|
-
|
|
Feb 24
2023
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
9,138
+8.11%
|
-
|
|
Feb 24
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
20,308
+9.74%
|
-
|
|
Feb 24
2023
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
22,339
+17.29%
|
-
|
|
Feb 23
2023
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
421
-2.43%
|
$10,104
$24.59 P/Share
|
|
Feb 23
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
1,893
-1.91%
|
$45,432
$24.59 P/Share
|
|
Feb 23
2023
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,422
-0.62%
|
$178,128
$24.59 P/Share
|
|
Feb 23
2023
|
Sheri Lewis EVP, Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
970
-1.48%
|
$23,280
$24.59 P/Share
|
|
Feb 23
2023
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-0.48%
|
$11,232
$24.59 P/Share
|
|
Feb 23
2023
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
569
-0.67%
|
$13,656
$24.59 P/Share
|